Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews' Q2 Loss Rises on Higher R&D Costs

NEW YORK (GenomeWeb News) – GeneNews today reported that its net loss rose 74 percent year over year on higher R&D costs as the firm rolled its first commercial biomarker test.
The Toronto-based firm brought in revenues of $288,438 for the three-month period ended June 30, compared to no revenues in the second quarter of 2007. It said revenue from the most recent quarter came from a collaboration with an Asian biomedical consortium to identify and validate a set of biomarkers for prostate disease.
"The launch of our first commercial product, ColonSentry, a blood test to assess a patient's current risk of having colorectal cancer, marks the completion of our company's transition into a fully commercial enterprise,” Heiner Dreismann, lead director and interim CEO of GeneNews, said in a statement.
"Over the coming quarters, our focus will be on driving adoption of ColonSentry in Canada, subsequent launches of the test in Asia, the United States and Europe, and further development of our pipeline of innovative molecular diagnostic tests for a range of disease indications,” he added.
GeneNews posted a net loss of $4 million, or $.07 per share, for the quarter compared to a loss of $2.3 million, or $.04 per share, in the comparable quarter of 2007.
The firm’s R&D expenses jumped to $3 million from $1.7 million year over year, and its SG&A spending increased 25.4 percent to $806,675 from $643,191.
GeneNews finished the quarter with $6.7 million in cash and cash equivalents. The firm said that it believes it has adequate resources to continue operating through the first quarter of 2009.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.